This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Web of Science (3) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Shoaf, S. E. Articles by Orlandi, C. Search for Related Content PubMed PubMed Citation Articles by Shoaf, S. E. Articles by Orlandi, C. Social Bookmarking                         What's this?

Tolvaptan Administration Does Not Affect Steady State Amiodarone Concentrations in Patients With Cardiac Arrhythmias

Otsuka Maryland Research Institute, Rockville, MD

Marcelo Víctor Elizari, MD

Hospital Ramos Mejía, Buenos Aires, Argentina

Zhao Wang, MD

Otsuka Maryland Research Institute, Rockville, MD

Kumara Sekar, PhD

Otsuka Maryland Research Institute, Rockville, MD

Liliana Rosa Grinfeld, MD

Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

N. Alejandro Barbagelata, MD

Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

Jorge Lerman, MD

Hospital de Clínicas de Buenos Aires, Buenos Aires, Argentina

Steven Lee Bramer, PhD

Otsuka Maryland Research Institute, Rockville, MD

Jorge Trongé, MD

Institutos Médicos Antártida, Buenos Aires, Argentina

Cesare Orlandi, MD

Otsuka Maryland Research Institute, Rockville, MD

Background: Tolvaptan, a nonpeptide selective vasopressin receptor (V₂) antagonist, is in development for the treatment of congestive heart failure and hyponatremia. Tolvaptan is primarily metabolized via CYP3A4. This study was conducted to determine the extent of the pharmacokinetic interaction between tolvaptan and steady state amiodarone, an antiarrhythmic drug commonly prescribed for patients with congestive heart failure and a known inhibitor of other drugs metabolized by CYP3A4.

Methods: This was a multicenter, open-label, 1-arm, 3-period, sequential treatment study conducted in 11 men (10) and women aged 49 to 80 years. They were primarily Caucasian (20) subjects, with a history of cardiac arrhythmias who were otherwise healthy. Subjects were to have been on oral amiodarone maintenance therapy of 200 mg/day for at least 10 months. All subjects took 200 mg amiodarone once daily on each study day; on days 3 and 4, they were also coadministered 30 and 90 mg of tolvaptan, respectively. The plasma concentrations of amiodarone and its metabolite desethylamiodarone were determined for 24 hours postdose on days 2, 3, and 4, tolvaptan concentrations were determined for 24 hours postdose on days 3 and 4.

Results: As determined by the ratio of the geometric means and 90% confidence intervals (0.5 to 2.0) for the maximal plasma concentration and the area under the curve during the dosing interval for both amiodarone and desethylamiodarone, tolvaptan coadministration had no effect on either amiodarone and desethylamiodarone disposition, as all the geometric mean ratios (amiodarone + tolvaptan [30 or 90 mg] vs amiodarone alone) were approximately 1.

Conclusion: Tolvaptan coadministration does not alter steady-state amiodarone or desethylamiodarone concentrations. Tolvaptan concentrations did not appear to be different from historical controls. The most frequently reported adverse event was polyuria (15 of 21 subjects for amiodarone + 30 mg tolvaptan); an expected outcome due to the known potent aquaretic action of tolvaptan. The combination of amiodarone and tolvaptan was well tolerated.

Key Words: amiodarone • cardiac failure • pharmacokinetic • plasma • tolvaptan

Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 10, No. 3, 165-171 (2005)
DOI: 10.1177/107424840501000304


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?